

# VALUE OF HOSPITAL PHARMACIST SERVICE IN THE OPTIMIZATION OF CAPECITABINE USE

DGI011

J.E. Poquet-Jornet<sup>1</sup>, C. Cuesta-Grueso<sup>1</sup>, A. Munilla-Das<sup>1</sup>, F.J. Carrera-Hueso<sup>2</sup>, S. Sanchez-Aranda<sup>1</sup>.

<sup>1</sup>Hospital Denia, Farmacia, Denia, Spain.

<sup>2</sup>Hospital Dr. Moliner, Farmacia, Valencia, Spain.

17 th EHP Congress. Milan, Italy 21-23 March 2012.

## Objectives

On November 12, 2009, the Valencian Health Agency ordered that certain drugs formerly available from pharmacies would from now on only be available from hospital pharmacies.

The aim of this study was to evaluate the economic impact derived from the change of dispensation of capecitabine (Xeloda ©) from the pharmacies to the hospital Pharmacies.

## Study design.

- ✓ We analyzed data of the dispensations of capecitabine made in pharmacies during 2009 and compared them with those obtained from our hospital electronic prescription program during 2010.
- ✓ There was no variation in the number of oncologists prescribing during both periods.
- ✓ Since the publication of the law, all oral gyrostatic prescriptions were validated by hospital pharmacists using the same criteria as used for intravenous drugs, and the exact number of tablets needed for each cycle was dispensed.

## Results

	patients	total euros	annual cost/patient
2009	42	276845	6752
2010	72	105215	1461

## Conclusions

- ✓ Adjusting the dose prescribed according to the patient's weight and optimizing the number of tablets dispensed, economical impact has decreased from 486164 theorist Euros in 2010 (6752 Euros / patient per 72 patients) to 105215 Euros.
- ✓ Final **annual saving of 380929 Euros (a whole decrease of 78.3%)**.
- ✓ The hospital pharmacist plays an important role in validating the clinical use of drugs and evaluating the economical impact of new therapies.